News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

Smaller, Faster Flow Cytometer Could Be Used by Clinical Laboratories in Community Hospitals to Support Personalized Medical Diagnostics

Researchers in Germany want to shrink flow cytometers—currently as large as home washing machines—down to the size of a shoebox, while making their device more accurate

Flow cytometers, essential to the diagnosis of blood cancers, are in for a major makeover, if researchers at a technology institute in Germany are successful at engineering a smaller, cheaper, and more automated version of today’s large and expensive flow cytometer systems. If this happens, it would make it possible for clinical laboratories in many community hospitals to use these more compact flow cytometers in support of patient care.

Flow cytometers have been around for about 40 years; however, the equipment is expensive, large, and the process so lengthy and complex that only specially-trained scientists can operate it. Those factors make it difficult for patients and clinicians to reap the full benefit of the information that flow cytometry can yield. (more…)

Pathologists and Research Team at Dana-Farber/Brigham and Women’s Use Next-Gen Sequencing to Create Faster, More Accurate Cancer Test

This advanced medical laboratory test looks for 95 genetic mutations associated with cancers of the blood and may provide pathologists with a new diagnostic tool 

Seeking a faster time to answer when diagnosing patients with cancers of the blood, researchers and pathologists at the Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) in Boston have developed a unique clinical laboratory assay that involves multiple genes and just takes days to perform.

This high-tech genetic diagnostic test is called Rapid Heme Panel. It scans DNA in blood or bone marrow specimens. It uses powerful next-gen sequencing technology that searches for 95 genes that frequently mutate in blood cancers, according to a press release issued by DF/BWCC.

At Dana-Farber/Brigham and Women’s cancer center, this medical laboratory test is used in patients with leukemia, Myelodysplastic syndromes caused by poorly formed or dysfunctional blood cells, and myeloproliferative disorders that fill the bone marrow with abnormal blood cells. (more…)

;